Mesothelioma chemotherapy is the treatment of malignant mesothelioma through the use of anticancer drugs. Mesothelioma treatments are divided into two categories; traditional mesothelioma treatments and new mesothelioma treatments. Chemotherapy falls into both categories. It has been used traditionally in the treatment of malignant mesothelioma and a variety of other cancers for decades. Mesothelioma research, as of late, has focused heavily on the development and implementation of new chemotherapy drugs that are based on a greater understanding of how mesothelioma metastasizes (spreads to other organs).
Alimta is the brand name for pemetrexed, a folate antimetabolites chemotherapy drug that is chemically similar to folic acid. Alimta is one of several newly developed chemotherapy drugs being tested for the treatment of mesothelioma. As a single agent, Alimta is used for the treatment of locally advanced or metastatic non-small cell lung cancers whose growth has not been slowed by traditional chemotherapy treatments. When Alimta is used in conjunction with cisplatin, it is the only Food and Drug Administration approved agent designated for specific use in combating malignant pleural mesothelioma. Learn more about Alimta.
Alimta prevents cellular growth by inhibiting three enzymes (thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyl transferase) that are essential in the body's formation of DNA and RNA.
For questions related to the foundation and to make contributions please contact:
(800) 909-Meso (6376)
3011 Townsgate Rd, Suite 450
Westlake Village, CA 91361
For more information and other questions contact:
©2017 Mesothelioma Research Foundation Of America